JP2014530246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530246A5 JP2014530246A5 JP2014536225A JP2014536225A JP2014530246A5 JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5 JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- sulfated glycosaminoglycan
- administered
- dose
- sulfated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 claims 23
- 102000001690 Factor VIII Human genes 0.000 claims 23
- 229960000301 factor viii Drugs 0.000 claims 23
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 21
- 230000037396 body weight Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548606P | 2011-10-18 | 2011-10-18 | |
| EP11185648.0 | 2011-10-18 | ||
| EP11185648 | 2011-10-18 | ||
| US61/548,606 | 2011-10-18 | ||
| PCT/EP2012/070615 WO2013057167A1 (en) | 2011-10-18 | 2012-10-18 | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530246A JP2014530246A (ja) | 2014-11-17 |
| JP2014530246A5 true JP2014530246A5 (enExample) | 2015-11-26 |
| JP6072810B2 JP6072810B2 (ja) | 2017-02-01 |
Family
ID=48140372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536225A Expired - Fee Related JP6072810B2 (ja) | 2011-10-18 | 2012-10-18 | 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9393289B2 (enExample) |
| EP (1) | EP2768522B1 (enExample) |
| JP (1) | JP6072810B2 (enExample) |
| KR (1) | KR20140083036A (enExample) |
| CN (1) | CN103889445A (enExample) |
| AU (1) | AU2012318279B2 (enExample) |
| CA (1) | CA2852397A1 (enExample) |
| DK (1) | DK2768522T3 (enExample) |
| ES (1) | ES2600081T3 (enExample) |
| WO (1) | WO2013057167A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012318303B2 (en) | 2011-10-18 | 2015-09-03 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII |
| DK3152230T3 (da) | 2014-06-06 | 2019-11-11 | Octapharma Ag | Præparat omfattende faktor viii og von willebrand-faktor-peptider |
| CN107135654B (zh) * | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| US10308705B2 (en) * | 2015-02-06 | 2019-06-04 | The University Of North Carolina At Chapel Hill | Optimized human clotting factor VIII gene expression cassettes and their use |
| SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| DE3683980D1 (de) | 1985-04-12 | 1992-04-02 | Genetics Inst | Neue prokoagulierungsproteine. |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| DE69740154D1 (de) | 1996-04-24 | 2011-05-05 | Univ Michigan | Gegen Inaktivierung resistenter Faktor VIII |
| WO2000024759A1 (en) | 1998-10-23 | 2000-05-04 | The Trustees Of The University Of Pennsylvania | Systemic delivery of gene products via skin |
| NZ530131A (en) | 2001-06-15 | 2005-12-23 | Andre C | Gene therapy for hemophilia A |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| ATE440619T1 (de) | 2003-05-06 | 2009-09-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie |
| EP2222329A1 (en) * | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| EP2626080A3 (en) | 2008-02-27 | 2014-03-05 | Novo Nordisk A/S | Conjugated factor VIII molecules |
| US20120148557A1 (en) * | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
-
2012
- 2012-10-18 US US14/352,540 patent/US9393289B2/en not_active Expired - Fee Related
- 2012-10-18 JP JP2014536225A patent/JP6072810B2/ja not_active Expired - Fee Related
- 2012-10-18 KR KR1020147013300A patent/KR20140083036A/ko not_active Withdrawn
- 2012-10-18 DK DK12777895.9T patent/DK2768522T3/en active
- 2012-10-18 EP EP12777895.9A patent/EP2768522B1/en not_active Not-in-force
- 2012-10-18 ES ES12777895.9T patent/ES2600081T3/es active Active
- 2012-10-18 WO PCT/EP2012/070615 patent/WO2013057167A1/en not_active Ceased
- 2012-10-18 AU AU2012318279A patent/AU2012318279B2/en not_active Ceased
- 2012-10-18 CN CN201280051236.7A patent/CN103889445A/zh active Pending
- 2012-10-18 CA CA2852397A patent/CA2852397A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2016517421A5 (enExample) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| NZ747657A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2016508123A5 (enExample) | ||
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2014530246A5 (enExample) | ||
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| JP2014530873A5 (enExample) | ||
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2013520447A5 (enExample) | ||
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| WO2019094823A8 (en) | Mitochondrial localization signals in human tafazzin and uses thereof | |
| WO2014145199A3 (en) | Retrograde delivery of sdf-1 for treatment of myocardial infarction | |
| MY163107A (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
| Marzuillo et al. | Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia |